Founded in 2015 and now headquartered in Boston, with a team of nearly 500 employees across multiple continents, this company develops artificial intelligence systems for remote patient monitoring and virtual care delivery. Its platform analyzes over 120 biomarkers in real time to identify subtle physiological changes and predict patient deterioration before symptoms manifest, enabling hospital-level care to be delivered at home.
The platform has been adopted by major health systems including AdventHealth and Orlando Health. Clinical outcomes reported in deployment include a 70% reduction in hospital readmissions, detection of patient deterioration approximately 21 hours sooner than conventional methods, and 38% cost savings. The company achieved unicorn valuation status in 2022 and merged with CopilotIQ in 2024.
Core technical capabilities span artificial intelligence, real-time biomarker analysis, predictive analytics, and digital health infrastructure. The company operates through offices in Singapore, Boston, and India.